Free tool
FAERS Monitor: Hycodan
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 005213 or its brand name (Hycodan, Homatropine Methylbromide, Hydrocodone Bitartrate). Reports on generic versions are filed under their own applications.
Reports
32
Serious
10
31% of reports
Hospitalization
1
Death reported
2
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- abdominal pain upper3
- constipation3
- decreased appetite3
- hypersensitivity3
- injection site rash3
- nausea3
- adverse drug reaction2
- chronic kidney disease2
- diarrhoea2
- dizziness2
- pain2
- somnolence2
- vomiting2
- ageusia1
- ataxia1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2008 | 1 |
| 2010 | 1 |
| 2014 | 1 |
| 2018 | 3 |
| 2019 | 3 |
| 2020 | 10 |
| 2021 | 4 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 5 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,127 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| injection site rashSignal | 3 | 64.3 | 21.9 | 129 |
| ataxia | 1 | 55.4 | 8.0 | 13 |
| ageusia | 1 | 26.4 | 3.8 | 6 |
| chronic kidney disease | 2 | 17.3 | 4.5 | 17 |
| adverse drug reaction | 2 | 14.6 | 3.8 | 14 |
| hypersensitivitySignal | 3 | 10.6 | 3.6 | 18 |
| abdominal pain upperSignal | 3 | 9.6 | 3.3 | 15 |
| constipationSignal | 3 | 9.0 | 3.1 | 14 |
| decreased appetiteSignal | 3 | 8.5 | 2.9 | 13 |
| somnolence | 2 | 6.5 | 1.7 | 5 |
| vomiting | 2 | 2.8 | 0.7 | 1 |
| dizziness | 2 | 2.6 | 0.7 | 1 |
| nausea | 3 | 2.5 | 0.8 | 1 |
| pain | 2 | 2.1 | 0.6 | 0 |
| diarrhoea | 2 | 2.0 | 0.5 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.